Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2009 1
2010 1
2013 5
2015 8
2016 13
2017 23
2018 27
2019 31
2020 34
2021 11
2022 11
2023 8
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

150 results

Results by year

Filters applied: . Clear all
Page 1
Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer.
Tintelnot J, Xu Y, Lesker TR, Schönlein M, Konczalla L, Giannou AD, Pelczar P, Kylies D, Puelles VG, Bielecka AA, Peschka M, Cortesi F, Riecken K, Jung M, Amend L, Bröring TS, Trajkovic-Arsic M, Siveke JT, Renné T, Zhang D, Boeck S, Strowig T, Uzunoglu FG, Güngör C, Stein A, Izbicki JR, Bokemeyer C, Sinn M, Kimmelman AC, Huber S, Gagliani N. Tintelnot J, et al. Nature. 2023 Mar;615(7950):168-174. doi: 10.1038/s41586-023-05728-y. Epub 2023 Feb 22. Nature. 2023. PMID: 36813961 Free PMC article.
CKD: A Call for an Age-Adapted Definition.
Delanaye P, Jager KJ, Bökenkamp A, Christensson A, Dubourg L, Eriksen BO, Gaillard F, Gambaro G, van der Giet M, Glassock RJ, Indridason OS, van Londen M, Mariat C, Melsom T, Moranne O, Nordin G, Palsson R, Pottel H, Rule AD, Schaeffner E, Taal MW, White C, Grubb A, van den Brand JAJG. Delanaye P, et al. J Am Soc Nephrol. 2019 Oct;30(10):1785-1805. doi: 10.1681/ASN.2019030238. Epub 2019 Sep 10. J Am Soc Nephrol. 2019. PMID: 31506289 Free PMC article. Review.
Among younger persons, mortality is increased at GFR <75 ml/min per 1.73 m(2), whereas in elderly people it is increased at levels <45 ml/min per 1.73 m(2) Therefore, we suggest that amending the CKD definition to include age-specific thresholds for GFR. ...
Among younger persons, mortality is increased at GFR <75 ml/min per 1.73 m(2), whereas in elderly people it is increased at levels <45 …
Early management of severe abdominal trauma.
Bouzat P, Valdenaire G, Gauss T, Charbit J, Arvieux C, Balandraud P, Bobbia X, David JS, Frandon J, Garrigue D, Long JA, Pottecher J, Prunet B, Simonnet B, Tazarourte K, Trésallet C, Vaux J, Viglino D, Villoing B, Zieleskiewicz L, Gil-Jardiné C, Weiss E. Bouzat P, et al. Anaesth Crit Care Pain Med. 2020 Apr;39(2):269-277. doi: 10.1016/j.accpm.2019.12.001. Epub 2019 Dec 13. Anaesth Crit Care Pain Med. 2020. PMID: 31843714 Free article.
RESULTS: The SFAR/SFMU Guideline panel provided 15 statements on early management of severe abdominal trauma. After three rounds of discussion and various amendments, a strong agreement was reached for 100% of recommendations. ...
RESULTS: The SFAR/SFMU Guideline panel provided 15 statements on early management of severe abdominal trauma. After three rounds of discussi …
Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation-SFAR).
Guilhaumou R, Benaboud S, Bennis Y, Dahyot-Fizelier C, Dailly E, Gandia P, Goutelle S, Lefeuvre S, Mongardon N, Roger C, Scala-Bertola J, Lemaitre F, Garnier M. Guilhaumou R, et al. Crit Care. 2019 Mar 29;23(1):104. doi: 10.1186/s13054-019-2378-9. Crit Care. 2019. PMID: 30925922 Free PMC article. Review.
Due to the lack of powerful studies having used mortality as main judgement criteria, it was decided, before drafting the recommendations, to formulate only "optional" recommendations. RESULTS: After two rounds of rating and one amendment, a strong agreement was reached by …
Due to the lack of powerful studies having used mortality as main judgement criteria, it was decided, before drafting the recommendations, t …
Early management of severe pelvic injury (first 24 hours).
Incagnoli P, Puidupin A, Ausset S, Beregi JP, Bessereau J, Bobbia X, Brun J, Brunel E, Buléon C, Choukroun J, Combes X, David JS, Desfemmes FR, Garrigue D, Hanouz JL, Plénier I, Rongieras F, Vivien B, Gauss T, Harrois A, Bouzat P, Kipnis E. Incagnoli P, et al. Anaesth Crit Care Pain Med. 2019 Apr;38(2):199-207. doi: 10.1016/j.accpm.2018.12.003. Epub 2018 Dec 21. Anaesth Crit Care Pain Med. 2019. PMID: 30579941 Free article. Review.
RESULTS: The SFAR Guideline panel provided 22 statements on prehospital and hospital management of the unstable patient with pelvic fracture. After three rounds of discussion and various amendments, a strong agreement was reached for 100% of recommendations. ...
RESULTS: The SFAR Guideline panel provided 22 statements on prehospital and hospital management of the unstable patient with pelvic fracture …
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis.
Curigliano G, Mueller V, Borges V, Hamilton E, Hurvitz S, Loi S, Murthy R, Okines A, Paplomata E, Cameron D, Carey LA, Gelmon K, Hortobagyi GN, Krop I, Loibl S, Pegram M, Slamon D, Ramos J, Feng W, Winer E. Curigliano G, et al. Ann Oncol. 2022 Mar;33(3):321-329. doi: 10.1016/j.annonc.2021.12.005. Epub 2021 Dec 23. Ann Oncol. 2022. PMID: 34954044 Free article. Clinical Trial.
After the primary analysis (median follow-up of 14 months), the protocol was amended to allow for unblinding sites to treatment assignment and cross-over from the placebo combination to the tucatinib combination. ...
After the primary analysis (median follow-up of 14 months), the protocol was amended to allow for unblinding sites to treatment assig …
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial.
Lu Z, Wang J, Shu Y, Liu L, Kong L, Yang L, Wang B, Sun G, Ji Y, Cao G, Liu H, Cui T, Li N, Qiu W, Li G, Hou X, Luo H, Xue L, Zhang Y, Yue W, Liu Z, Wang X, Gao S, Pan Y, Galais MP, Zaanan A, Ma Z, Li H, Wang Y, Shen L; ORIENT-15 study group. Lu Z, et al. BMJ. 2022 Apr 19;377:e068714. doi: 10.1136/bmj-2021-068714. BMJ. 2022. PMID: 35440464 Free PMC article. Clinical Trial.
INTERVENTION: Participants were randomised 1:1 to receive sintilimab or placebo (3 mg/kg in patients weighing <60 kg or 200 mg in patients weighing 60 kg) in combination with cisplatin 75 mg/m(2) plus paclitaxel 175 mg/m(2) every three weeks. The trial was amended to al …
INTERVENTION: Participants were randomised 1:1 to receive sintilimab or placebo (3 mg/kg in patients weighing <60 kg or 200 mg in patient …
Guidelines on muscle relaxants and reversal in anaesthesia.
Plaud B, Baillard C, Bourgain JL, Bouroche G, Desplanque L, Devys JM, Fletcher D, Fuchs-Buder T, Lebuffe G, Meistelman C, Motamed C, Raft J, Servin F, Sirieix D, Slim K, Velly L, Verdonk F, Debaene B. Plaud B, et al. Anaesth Crit Care Pain Med. 2020 Feb;39(1):125-142. doi: 10.1016/j.accpm.2020.01.005. Epub 2020 Jan 8. Anaesth Crit Care Pain Med. 2020. PMID: 31926308 Free article.
No recommendations could be provided using the GRADE system for five of the questions, and for two of these questions expert opinions were given. After two rounds of discussion and an amendment, a strong agreement was reached for all the recommendations. ...
No recommendations could be provided using the GRADE system for five of the questions, and for two of these questions expert opinions were g …
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
Beck LA, Deleuran M, Bissonnette R, de Bruin-Weller M, Galus R, Nakahara T, Seo SJ, Khokhar FA, Vakil J, Xiao J, Marco AR, Levit NA, O'Malley JT, Shabbir A. Beck LA, et al. Am J Clin Dermatol. 2022 May;23(3):393-408. doi: 10.1007/s40257-022-00685-0. Epub 2022 May 3. Am J Clin Dermatol. 2022. PMID: 35503163 Free PMC article.
METHODS: This interim analysis of the open-label extension study (NCT01949311) evaluated dupilumab 300 mg qw or q2w in adults previously enrolled in dupilumab trials for moderate-to-severe AD. Patients switched from qw to q2w following protocol amendment. The primary outco …
METHODS: This interim analysis of the open-label extension study (NCT01949311) evaluated dupilumab 300 mg qw or q2w in adults previously enr …
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.
Holmes FA, Moy B, Delaloge S, Chia SKL, Ejlertsen B, Mansi J, Iwata H, Gnant M, Buyse M, Barrios CH, Silovski T, Šeparović R, Bashford A, Zotano AG, Denduluri N, Patt D, Gokmen E, Gore I, Smith JW 2nd, Loibl S, Masuda N, Tomašević Z, Petráková K, DiPrimeo D, Wong A, Martin M, Chan A; ExteNET Study Group. Holmes FA, et al. Eur J Cancer. 2023 May;184:48-59. doi: 10.1016/j.ejca.2023.02.002. Epub 2023 Feb 10. Eur J Cancer. 2023. PMID: 36898233 Free article. Clinical Trial.
METHODS: In this international, randomised, double-blind, placebo-controlled, phase 3 trial, women aged 18 years or older with stage 1-3c (amended to stage 2-3c) HER2-positive breast cancer who had completed neoadjuvant and adjuvant chemotherapy plus trastuzumab were eligi …
METHODS: In this international, randomised, double-blind, placebo-controlled, phase 3 trial, women aged 18 years or older with stage 1-3c ( …
150 results